Please assess the completion status of the following clinical trial:

Trial Title: Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lobar-only treatments~* Patients with biopsy or radiographically proven hepatocellular carcinoma who are not candidates for transplant, surgical resection or ablative therapy~* Patients 18 years of age and older~* Patients who are able to provide written informed consent~Exclusion Criteria:~* Patients with Barcelona-Clinic Liver Cancer (BCLC) Stage C disease,~* Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3,~* Patients who are unable to tolerate Y-90,~* Patients with arterial anatomy unsuitable to place Surefire catheter,~* Patients with uncorrectable coagulopathy,~* Patients with platelets less than 50 (uncorrectable),~* Bilirubin \>3 mg/dl,~* AST or ALT\>5x upper limit of normal,~* Patients who are unable to tolerate angiography,~* Patients with \< 3 months to live,~* Patients who meet the standard Y-90 exclusion criteria according to package insert~* Female patients who are pregnant~* Patients under the age of 18~* Patients who are unable to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surefire® Infusion System (Type: EXPERIMENTAL): Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
- Standard End-hole catheter (Type: ACTIVE_COMPARATOR): Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).